FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma March 7, 2022 Auto Bot News 0 FDA approved ciltacabtagene autoleucel (CARVYKTI, Janssen Biotech, Inc.) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy.